Experimental Study On The Killing Effect Of Cetuximab Combined With NK Cells On Breast Cancer Cells In Vitro

Objective: To investigate whether Cetuximab combined with NK cells has a synergistic effect on the killing effect of breast cancer cells in vitro,and explore its mechanism.The NK cell surface activated receptor Fc?RIII and tumor cell cell surface EGFR receptor expression were used as a link to provide an experimental basis for the cell biological treatment of Cetuximab-linked NK cells.Methods: Breast cancer cell line MDA-MB-231 was cultured in vitro,and the control group,Cetuximab group,NK cell group,and combination group were set up respectively;CCK-8method was used to detect Cetuximab and NK cells against breast cancer MDA-Effects of MB-231 cell proliferation;flow cytometry was used to detect the expansion effect and phenotype of NK cells,and the inhibitory effect of human peripheral blood-derived NK cells on tumor cells expanded in vitro was detected;LDH method was used to detect three groups Changes in inhibition rate of MDA-MB-231 cells after treatment with different factors.Results:(1)Cetuximab significantly inhibited the proliferation of EGFR-positive breast cancer cells in a dose-and time-dependent manner.(2)In vitro killing effect of NK cells on human breast cancer MDA-MB-231 cells.(3)Cetuximab and NK cells have a synergistic effect on the killing of human breast cancer MDA-MB-231 cells.Conclusion: Cetuximab can significantly inhibit the proliferation of EGFR-positive breast cancer cells and is closely related to the level of EGFR expression on the surface of breast cancer cells.Cetuximab and NK cells have a synergistic effect on the killing effect of EGFR-positive breast cancer cells.May be related to Cetuximab increasing cytotoxicity of NK cells.Therefore,for patients with EGFR-positive breast cancer,the combined use of Cetuximab and NK cell adoptive therapy may become an effective treatment method.